Search research articles
Contact Us
Filters
Showing results (51-60 of 135) with videos related to
Page
of 14
Sort By:
Clinical Pharmacokinetics
|
April 19, 2020
Pharmacokinetic Profile of Gilteritinib: A Novel FLT-3 Tyrosine Kinase Inhibitor
Angela Joubert James, Catherine C Smith, Mark Litzow, et al.
Clinical Pharmacokinetics
|
July 23, 2021
Correction to: Pharmacokinetic Profile of Gilteritinib: A Novel FLT-3 Tyrosine Kinase Inhibitor
Angela Joubert James, Catherine C Smith, Mark Litzow, et al.
Haematologica
|
February 10, 2022
Outcome of relapsed or refractory acute B-lymphoblastic leukemia patients and <i>BCR-ABL</i>-positive blast cell crisis of B-lymphoid lineage with extramedullary disease receiving inotuzumab ozogamicin
Sabine Kayser, Chiara Sartor, Marlise R Luskin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 23, 2009
New lesions detected by single nucleotide polymorphism array-based chromosomal analysis have important clinical impact in acute myeloid leukemia
Ramon V Tiu, Lukasz P Gondek, Christine L O'Keefe, et al.
Haematologica
|
December 24, 2013
A phase II trial of sequential ribonucleotide reductase inhibition in aggressive myeloproliferative neoplasms
Joshua F Zeidner, Judith E Karp, Amanda L Blackford, et al.
Oncogene
|
September 2, 2018
Hedgehog/GLI1 activation leads to leukemic transformation of myelodysplastic syndrome in vivo and GLI1 inhibition results in antitumor activity
Bonnie W Lau, Kyounghee Huh, Rafael Madero-Marroquin, et al.
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners
|
June 17, 2021
Arsenic trioxide dose capping to decrease toxicity in the treatment of acute promyelocytic leukemia
Kyle Zacholski, Bryan Hambley, Erin Hickey, et al.
Transplantation and Cellular Therapy
|
October 5, 2020
Clinical Outcomes in Patients with FLT3-ITD-Mutated Relapsed/Refractory Acute Myelogenous Leukemia Undergoing Hematopoietic Stem Cell Transplantation after Quizartinib or Salvage Chemotherapy in the QuANTUM-R Trial
Siddhartha Ganguly, Jorge E Cortes, Alwin Krämer, et al.
Leukemia & Lymphoma
|
June 16, 2020
Clustered incidence of adult acute promyelocytic leukemia in the vicinity of Baltimore
Andrew Y Li, Sarah M Kashanian, Bryan C Hambley, et al.
Science Advances
|
February 18, 2022
The role of the atypical chemokine receptor CCRL2 in myelodysplastic syndrome and secondary acute myeloid leukemia
Theodoros Karantanos, Patric Teodorescu, Brandy Perkins, et al.
Page
of 14
Search research articles
Search
Showing results (51-60 of 135) with videos related to
Sort By:
Page
of 14
Clinical Pharmacokinetics
|
April 19, 2020
Pharmacokinetic Profile of Gilteritinib: A Novel FLT-3 Tyrosine Kinase Inhibitor
Angela Joubert James, Catherine C Smith, Mark Litzow, et al.
Clinical Pharmacokinetics
|
July 23, 2021
Correction to: Pharmacokinetic Profile of Gilteritinib: A Novel FLT-3 Tyrosine Kinase Inhibitor
Angela Joubert James, Catherine C Smith, Mark Litzow, et al.
Haematologica
|
February 10, 2022
Outcome of relapsed or refractory acute B-lymphoblastic leukemia patients and <i>BCR-ABL</i>-positive blast cell crisis of B-lymphoid lineage with extramedullary disease receiving inotuzumab ozogamicin
Sabine Kayser, Chiara Sartor, Marlise R Luskin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 23, 2009
New lesions detected by single nucleotide polymorphism array-based chromosomal analysis have important clinical impact in acute myeloid leukemia
Ramon V Tiu, Lukasz P Gondek, Christine L O'Keefe, et al.
Haematologica
|
December 24, 2013
A phase II trial of sequential ribonucleotide reductase inhibition in aggressive myeloproliferative neoplasms
Joshua F Zeidner, Judith E Karp, Amanda L Blackford, et al.
Oncogene
|
September 2, 2018
Hedgehog/GLI1 activation leads to leukemic transformation of myelodysplastic syndrome in vivo and GLI1 inhibition results in antitumor activity
Bonnie W Lau, Kyounghee Huh, Rafael Madero-Marroquin, et al.
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners
|
June 17, 2021
Arsenic trioxide dose capping to decrease toxicity in the treatment of acute promyelocytic leukemia
Kyle Zacholski, Bryan Hambley, Erin Hickey, et al.
Transplantation and Cellular Therapy
|
October 5, 2020
Clinical Outcomes in Patients with FLT3-ITD-Mutated Relapsed/Refractory Acute Myelogenous Leukemia Undergoing Hematopoietic Stem Cell Transplantation after Quizartinib or Salvage Chemotherapy in the QuANTUM-R Trial
Siddhartha Ganguly, Jorge E Cortes, Alwin Krämer, et al.
Leukemia & Lymphoma
|
June 16, 2020
Clustered incidence of adult acute promyelocytic leukemia in the vicinity of Baltimore
Andrew Y Li, Sarah M Kashanian, Bryan C Hambley, et al.
Science Advances
|
February 18, 2022
The role of the atypical chemokine receptor CCRL2 in myelodysplastic syndrome and secondary acute myeloid leukemia
Theodoros Karantanos, Patric Teodorescu, Brandy Perkins, et al.
Page
of 14